+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Zydus Cadila - logo

Zydus Cadila Pharmaceutical is a global healthcare provider. The origins of this group go back to 1952, however in 1995 this group restructured its operations and the Cadila group were taken over by the Zydus group. It is the only Indian pharma company to launch its own patented NCE. They developed a drug for diabetic dyslipidemia, Lipaglyn. This is the first drug to be approved for this disease. They are the 4th largest in the Indian pharma market. Other than their successful sales from India, Zydus gains a wider market share through its subsidiaries in the U.S, Europe (France and Spain), South Africa and Latin America. From their beginning in 1995 to today Zydus has shown major growth rates in revenue.

Pegfilgrastim- Biosimilar Insight, 2022 - Product Thumbnail Image

Pegfilgrastim- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Filgrastim - Biosimilar Insight, 2022 - Product Thumbnail Image

Filgrastim - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 70 Pages
  • Global
From
Chemotherapy Induced Anemia - Pipeline Insight, 2024 - Product Thumbnail Image

Chemotherapy Induced Anemia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
From
From
From
Antifibrinolytic Drugs Market - Forecasts from 2020 to 2025 - Product Thumbnail Image

Antifibrinolytic Drugs Market - Forecasts from 2020 to 2025

  • Report
  • April 2020
  • 115 Pages
  • Global
From
Antibacterial Drugs Market Report 2024-2034 - Product Thumbnail Image

Antibacterial Drugs Market Report 2024-2034

  • Report
  • January 2024
  • 269 Pages
  • Global
From
From
Loading Indicator